Securities Lawsuit Filed Against Aquestive Over Anaphylm Drug Application Misstatements

Rosen Law Firm, a leading investor rights firm, is actively recruiting lead plaintiffs for a securities class action lawsuit against Aquestive Therapeutics, Inc. ($AQST), alleging the pharmaceutical company made material misrepresentations regarding its regulatory submission for Anaphylm. The lawsuit centers on claims that Aquestive concealed critical deficiencies related to human factors in the sublingual film's packaging, use, administration, and labeling during the New Drug Application (NDA) process. Investors who purchased company securities during a specific window spanning from June 16, 2025 through January 8, 2026 may be eligible to participate in potential settlements, though a critical deadline of May 4, 2026 looms for lead plaintiff certification.

The Allegations and Case Details

The securities class action targets alleged disclosure failures surrounding the Anaphylm product, a sublingual film formulation designed to treat severe allergic reactions. According to the complaint framework established by Rosen Law Firm, Aquestive allegedly failed to adequately disclose human factors issues that could affect the drug's safe and effective use. These concerns encompassed multiple dimensions of the product's design and presentation:

• Packaging design deficiencies that may not have met FDA human factors validation standards
• Use and administration concerns related to patient comprehension and proper dosing
• Labeling inadequacies potentially failing to communicate critical safety information

The material omissions are alleged to have directly impacted the company's regulatory pathway, as the FDA's human factors assessment is a cornerstone requirement for sublingual and other orally-administered medications. When such deficiencies surface post-disclosure, stock prices typically experience sharp declines due to increased regulatory risk and delayed commercialization timelines.

Investors who accumulated Aquestive securities during the 17-month period from June 16, 2025 to January 8, 2026 represent the putative class membership. The triggering event—the revelation of these human factors issues—presumably occurred on or around January 8, 2026, creating the price-sensitive disclosure that prompted the lawsuit filing.

Market Context and Regulatory Landscape

The allegations against Aquestive reflect broader scrutiny within the biopharmaceutical sector regarding regulatory disclosure practices and quality assurance protocols. Human factors engineering has become increasingly critical in FDA evaluations, particularly for novel drug delivery systems like sublingual films, which require specific patient behaviors for proper administration.

Key market considerations:

• The FDA emphasizes human factors validation to prevent medication errors and ensure patient safety
• Biotech companies face heightened disclosure obligations regarding regulatory interactions and potential NDA deficiencies
• Sublingual film technologies represent a competitive space with multiple players developing similar formulations
• Delayed or rejected NDAs can significantly impact timelines for product commercialization and revenue generation

For a company like Aquestive, which has positioned Anaphylm as a core product candidate, regulatory setbacks directly threaten corporate valuation and investor confidence. The securities lawsuit suggests that investors may not have received adequate warnings about the human factors challenges that could complicate FDA approval.

Investor Implications and Damages Exposure

The lawsuit carries material implications for Aquestive Therapeutics shareholders and the broader investment community. Lead plaintiff designations typically precede settlement negotiations or trial proceedings, with potential damages claims based on stock price depreciation during the class period and investor reliance on allegedly false or misleading statements.

Why this matters for investors:

• Stock volatility risk: Securities lawsuits create uncertainty around company valuations and can trigger additional sell-offs
• Capital allocation impact: Legal defense costs and potential settlements reduce available capital for R&D and commercialization
• Regulatory credibility: Successful litigation suggests material breaches in disclosure practices, raising questions about management integrity
• Compensation opportunity: Class members may recover a portion of documented losses if the case settles or succeeds at trial
• Future disclosure scrutiny: Regulatory agencies and institutional investors may increase oversight of the company's future SEC filings

For potential class members, the May 4, 2026 lead plaintiff deadline represents a critical juncture. Investors must secure legal representation and file appropriate motions to be considered for lead plaintiff status, which carries both the responsibility of representing the broader class and potential direct benefits from any recovery.

The case also underscores the importance of due diligence regarding regulatory communication practices. Companies must ensure that material information about potential NDA deficiencies, human factors assessments, and manufacturing issues are promptly and accurately disclosed to prevent investor reliance on incomplete information.

Looking Forward

As the securities class action against Aquestive Therapeutics progresses toward lead plaintiff certification, investors in the biopharmaceutical sector should monitor regulatory disclosures with heightened attention to human factors assessments and FDA communications. The lawsuit reinforces that material omissions regarding drug development challenges and regulatory obstacles can expose companies to substantial litigation risk and shareholder damages claims.

Investors who believe they have suffered losses from purchasing Aquestive securities during the class period should consult with securities counsel promptly to understand their rights and eligibility before the May deadline. As regulatory standards continue evolving and investor protections strengthen, biopharmaceutical companies face mounting pressure to maintain transparent, comprehensive disclosure practices throughout the drug development and regulatory approval process.